Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

Diabetes Technology and Therapeutics

Volumn 14, Issue 10, 2012, Pages 904-911

  Romley, John A ^a,b   Goldman, Dana P ^a,b   Solomon, Matthew ^c   McFadden, Daniel ^a   Peters, Anne L ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4;

ACUTE PANCREATITIS; ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PANCREATITIS; PEPTIDES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES; VENOMS;

EID: 84867053241     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0075     Document Type: Article

References (23)

1. U.S. Food and Drug Administration: Byetta Product Label. 2008. www.accessdata.fda.gov/drugsatfda-docs/label/2009/021773s9s11s18s22s25lbl.pdf (accessed July 8, 2012).
2. U.S. Food and Drug Administration MedWatch: MedWatch Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. 2008. www.fda.gov/Safety/Med-Watch/default.htm (accessed July 8, 2012).
3. Denker PS, Dimarco PE: Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471.
4. Ayoub WA, Kumar AA, Naguib HS, Taylor HC: Exenatide- induced acute pancreatitis. Endocr Pract 2010;16: 80-83.
5. Gonzalez-Perez A, Schlienger RG, Rodriguez LA: Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010;33:2580-2585.
6. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, Katz L: Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12: 766-771.
7. Dore DD, Seeger JD, Arnold Chan K: Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019- 1027.
8. Garg R, Chen W, Pendergrass M: Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-2354.
9. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD: A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-566.
10. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC: Pancreatitis, pancreatic, and thyroid cancer with glucagonlike peptide-1-based therapies. Gastroenterology 2011;141: 150-156.
11. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB: The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027- 2031.
12. Joyce GF, Escarce JJ, Solomon MD, Goldman DP: Employer drug benefit plans and spending on prescription drugs. JAMA 2002;288:1733-1739.
13. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004; 291:2344-2350.
14. Solomon MD, Goldman DP, Joyce GF, Escarce JJ: Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med 2009;169:740-748.
15. Goldman D, Joyce G, Karaca-Mandic P: Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-28.
16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
17. Steinberg W, Tenner S: Acute pancreatitis. N Engl J Med 1994;330:1198-1210.
18. Graubard BI, Korn EL: Predictive margins with survey data. Biometrics 1999;55:652-659.
19. McClellan M, McNeil BJ, Newhouse JP: Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994;272:859-866.
20. U.S. Food and Drug Administration: Adverse Event Reporting System 2012. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrug Effects/default.htm (accessed July 8, 2012).
21. Yadav D, Dhir R: How accurate are ICD-9 codes for acute (Ap) and chronic (Cp) pancreatitis? - A large VA Hospital experience. Pancreas 2006;33:508.
22. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.
23. Stulc T, Sedo A: Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88: 125-131.